IGF-1 LR3 vs IGF-1 LR3

Native IGF-1 wins for rapid-onset, pulse-style administration, and site-specific (local) hypertrophy with minimal systemic spillover. The short half-life makes it ideal for tightly targeted protocols and lower overall mitogenic concern.

IGF-1 LR3 wins for sustained systemic elevation of IGF-1 activity, superior muscle protein synthesis per dose, and convenience (once-daily SubQ administration). It resists IGF-binding proteins, resulting in longer and more potent anabolic signaling, making it the clear pick for full-body muscle accrual and synergy in advanced "trinity" stacks.

Pick native IGF-1 if:

• Site-specific hypertrophy or repair (e.g., direct IM/local administration near a target muscle)
• Short dosing windows desired for controlled pulse exposure
• Lower risk profile needed for research with minimal systemic IGF-1 elevation
• Interest in autocrine/paracrine effects over systemic action
• Longer-term, lower-potency applications where minimized mitogenic risk is a priority

Pick IGF-1 LR3 if:

• Maximizing systemic anabolism and muscle recovery in short pulses (3–6 week protocols)
• Part of a GH/insulin/IGF synergy stack for advanced physique research
• Convenience of once-daily dosing and prolonged activity (~20–30 hour half-life)
• Objectives include fast, robust lean mass accrual at the cost of more pronounced biologic activity
• Requiring IGF-1 activity that is less susceptible to binding proteins and more bioavailable per dose